**SUPPLEMENTARY MATERIALS**

**Supplementary Table 1.** Frequency of *FCGR* genotypes and HWE test.

We confirmed that the frequency of the *FCGR* SNPs genotyped in this study for *FCGR3A*, *FCGR2A* and *FCGR2C* were consistent with prior reported allelic frequencies for these SNPs (13, 16, 22-25). Mellor et al. note some reports of FCGR3A frequencies that did not agree with the Hardy-Weinberg Equilibrium (HWE), while other prior reports were in agreement with the HWE (33). For the *FCGR3A* SNP, we confirmed that our SNP frequencies were consistent with the *FCGR3A* SNP frequencies that Mellor et al. found that were in agreement with HWE. Finally, using the Chi-square method to assess HWE, we determined that our genotype frequencies for each FCGR allele respect the HWE (32). The HWE results were computed using the program from www.oege.org/software/hwe-mr-calc.shtml (50). The null hypothesis is that the population is in HWE, and the alternative hypothesis is that the population is *not* in HWE. Since the chi-squared values are less than 3.84 (p > 0.05), we failed to reject the null hypothesis that the population is in HWE.



**Supplementary Table 2.** PFS Clinical Outcome Assessment of *FCGR2A*, *FCGR3A* and *FCGR2C* SNPs.

The PFS for each individual FCGR, as well as FCGR combinations, were compared.



**Supplementary Table 3.** Clinical Outcome Parameters were Assessed for *FCGR3A*, *FCGR2A* and *FCGR2C* SNPs within the Group of 100 Patients with Clear Cell Histology that were Genotyped.

The amount of % tumor shrinkage (n=98), OS (n=100), PFS (n=100) and DCR (n=98) for each individual FCGR, as well as FCGR combinations, were compared.

****